CO 26749

Drug Profile

CO 26749

Alternative Names: GMA 839; WAY 141839

Latest Information Update: 29 Sep 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Purdue Pharma
  • Developer Purdue Pharma; Wyeth
  • Class Anxiolytics; Pregnanes
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 28 Sep 2006 Discontinued - Preclinical for Anxiety disorders in USA (unspecified route)
  • 23 Dec 2002 This compound is still in active development
  • 20 Mar 2002 American Home Products and its subsidiary Wyeth-Ayerst are both now called Wyeth
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top